Evidence map›Paper›PMID 37152950›Full record

ReviewFrontiers in endocrinology2023

Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response.

Maria Cristina Campopiano, Arianna Ghirri, Alessandro Prete, Loredana Lorusso, Luciana Puleo, Virginia Cappagli, Laura Agate, Valeria Bottici, Sandra Brogioni, Carla Gambale and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maria Cristina CampopianoUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Arianna GhirriUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandro PreteUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Loredana LorussoUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Luciana PuleoUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Virginia CappagliUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Laura AgateUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Valeria BotticiUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sandra BrogioniUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Carla GambaleUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Elisa MinaldiUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Antonio MatroneUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Rossella EliseiUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Eleonora MolinaroUnit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the differentiated thyroid cancer (DTC) management is shifted toward a tailored approach based on the estimated risks of recurrence and disease-specific mortality. While the current recommendations on the management of metastatic and progressive DTC are clear and unambiguous, the management of slowly progressive or indeterminate disease varies according to different centers and different physicians. In this context, active surveillance (AS) becomes the main tool for clinicians, allowing them to plan a personalized therapeutic strategy, based on the risk of an unfavorable prognosis, and to avoid unnecessary treatment. This review analyzes the main possible scenarios in treated DTC patients who could take advantage of AS.

Indexed as

AdenocarcinomaThyroid NeoplasmsHumansIodine RadioisotopesPrognosisWatchful WaitingIodine Radioisotopesactive surveillanceradioiodinerate of growthrecurrencethyroid cancer

Identifiers

PMID37152950
PMCPMC10157216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.